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ABSTRACT
Tumours defective in the DNA homologous recombination repair pathway can 
be effectively treated with poly (ADP-ribose) polymerase (PARP) inhibitors; these 
have proven effective in clinical trials in patients with BRCA gene function-defective 
cancers. However, resistance observed in both pre-clinical and clinical studies is likely 
to impact on this treatment strategy. Over-expression of phosphoglycoprotein (P-gp) 
has been previously suggested as a mechanism of resistance to the PARP inhibitor 
olaparib in mouse models of Brca1/2-mutant breast cancer. Here, we report that in a 
Brca2 model treated with olaparib, P-gp upregulation is observed but is not sufficient 
to confer resistance. Furthermore, resistant/relapsed tumours do not show substantial 
changes in PK/PD of olaparib, do not downregulate PARP1 or re-establish double 
stranded DNA break repair by homologous recombination, all previously suggested as 
mechanisms of resistance. However, resistance is strongly associated with epithelial-
mesenchymal transition (EMT) and treatment-naïve tumours given a single dose of 
olaparib upregulate EMT markers within one hour. Therefore, in this model, olaparib 
resistance is likely a product of an as-yet unidentified mechanism associated with 
rapid transition to the mesenchymal phenotype. 
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INTRODUCTION
Cancer cells with specific defective DNA-damage 
response pathways show synthetic lethality with 
inhibition of PARP, a key enzyme in single strand break 
repair [1, 2]. PARP inhibitors, such as olaparib, harness 
this principle to selectively kill BRCA-deficient cells. 
Olaparib has demonstrated excellent anti-tumour activity 
in Brca-mutated breast cancer models [3, 4] and clinical 
trials in BRCA-mutated cancer patients have also proven 
efficacious, leading to the approval of olaparib in over 
60 countries world-wide (https://www.lynparza.com). 
Both preclinical and clinical evidence also suggest activity 
in non-BRCA homologous recombination repair (HRR) 
defective backgrounds [5, 6].
The synthetic lethal interactions of olaparib with 
BRCA1 and BRCA2 defects remain a key area of interest. 
Resistance to olaparib has been seen in pre-clinical 
Brca-mutant mammary models [3, 4] and has also been 
reported in the clinical setting [7]. Elucidation of the 
diverse mechanisms of resistance to PARP inhibition is 
imperative, so that new approaches for more accurate 
patient stratification for potential novel combinations or 
follow-up therapies may be identified. 
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Here, we have investigated the effects of olaparib 
in an established BlgCre Brca2/Tp53-mutant mouse 
mammary model [3]. We analyzed a number of established 
olaparib-resistance mechanisms, including up-regulation 
of efflux pumps [4, 8], restoration of HRR [7, 9, 10] and 
loss of PARP1 [11]. We have found that the initial response 
to olaparib treatment is a very rapid (within one hour of 
treatment) activation of a mesenchymal-like differentiation 
program and, indeed, that either an initial weak response 
to olaparib treatment, or acquired resistance following an 
initial good response, correlated primarily with epithelial-
to-mesenchymal transition (EMT), where epithelial cells 
lose their cell-cell adhesion and apical-basal polarity 
and convert into mesenchymal-like cells. Tumours with 
EMT features have been shown to be highly resistant to 
chemotherapies [12, 13] and our data suggest that EMT 
is associated with both intrinsic and acquired resistance to 
olaparib. As previously reported, up-regulation of P-gp was 
also associated with resistance [3, 8]. However, inhibition 
of efflux pumps in our olaparib-resistant tumours had no 
effect on relapse and resistant/relapsed tumours did not have 
substantial changes in olaparib PK/PD or re-establish HRR 
[10]. Therefore, in this model, olaparib resistance is likely a 
product of an as-yet unidentified mechanism associated with 
the mesenchymal phenotype. 
RESULTS
Treatment-naïve BlgCre Brca2/Tp53-mutant 
tumours show a range of histological phenotypes
We have previously shown that mammary tumours 
in a Brca2-mutant mouse model generally respond well to 
olaparib, but that eventually tumours relapse on treatment 
[3]. To begin to identify possible relevant mechanisms 
that drive resistance, we first carried out a detailed 
histopathological analysis of olaparib-naïve and relapsed/
resistant tumours from the BlgCre Brca2/Tp53-mutant 
mouse mammary model, based on H&E appearance and 
immunohistochemical staining for KRT14, KRT18, TP63 
and VIM and using our previous histotype classification 
system [14, 15] (Tables 1 and 2; Figures 1–4).
Consistent with our previous studies [15], assessment 
of histopathological phenotypes in a cohort of 20 naïve 
tumours classified seven as adenocarcinoma/invasive 
ductal carcinoma of no special type (AC/IDC-NST, 
hereafter AC(NST), 35%), eight as adenomyoepithelioma 
(AME, 40%), two as adenosquamous carcinoma (ASQC, 
10%) and three as carcinosarcoma/metaplastic spindle 
cell carcinoma (MSCC, 15%). All tumours were ESR1α-
negative, although ESR1α-positive cells could be observed 
in normal epithelial ducts (not shown). In addition to a 
high percentage of VIM-positive tumour cells, MSCCs 
had a low percentage of CDH1-positive cells and a high 
percentage of TWIST1-, ZEB1- and ZEB2-positive cells, 
characteristic of EMT (Figure 5A–5E).
Resistance to olaparib is characterised by 
epithelial–mesenchymal transition
Next, we compared the phenotypes of the 20 naïve 
tumours versus 28 tumours that initially responded but 
then relapsed (relapsed/resistant tumours). We observed 
a significant change in the proportions of tumour 
phenotypes. MSCCs, that composed just 15% of the naïve 
tumours, accounted for ~60% in the relapsed cohort. On 
the contrary, AMEs were 40% of naïve tumors, versus 
6% of relapsed tumours (Table 2; Figure 5F, p < 0.001). 
Furthermore, relapsed AC(NST)s had significantly more 
VIM-positive cells than treatment-naïve tumours of 
a similar phenotype, which a similar trend was seen in 
AMEs (although this did not reach significance; Table 2, 
Figures 1 and 4A). Interestingly, relapsed MSCCs had 
increased KRT18-positive cells relative to treatment-naïve 
MSCCs (Table 2, Figures 1, 2 and 4B). Some relapsed 
MSCCs contained small regions with histopathological 
features that resembled AC(NST) or AME, contributing 
to the increased KRT18-positivity in these tumours, but 
some spindle cells also showed KRT18 staining. It is not 
possible to determine if these findings in relapsed MSCCs 
are due to pre-existing fusiform cells upregulating KRT18 
in response to therapy, or whether these KRT18-positive 
fusiform cells are in fact epithelial cells which have 
undergone a partial EMT and retained some epithelial 
marker expression.
Immunohistochemical analysis of the EMT-
associated transcription factors ZEB1, ZEB2, TWIST1 
and SNAIL2 in relapsed AC(NST)s (Figure 5B–5E) 
demonstrated a significant increase in ZEB1 staining 
(p = 0.03). Moreover, three out of six tumours analyzed 
showed increased TWIST1 staining compared to naïve 
AC(NST)s (although there were no differences in SNAI2 
or ZEB2 staining). Resistant MSCCs and AMEs showed 
no significant differences in ZEB1 or TWIST1 compared 
to naïve tumours (Figure 5).
Olaparib-responsive epithelial tumours express 
VIM 
While extended olaparib treatment in this model 
inevitably results in resistance of tumours to therapy 
and relapse, the initial response to treatment was 
heterogeneous. Tumour response to olaparib over the 
first 30 days of treatment could be classified as: excellent 
responders, which show a decrease in size; moderate 
responders, which stop growing but do not decrease 
substantially in size; and poor responders (including non-
responders) which continue to grow similarly to the no-
drug control (Figure 6A). Most tumours showed at least a 
moderate response, with poor responders being rare. 
To strengthen the correlation between EMT and 
resistance, and determine whether tumour histopathology 
correlated with response categories, a cohort of 47 tumours 
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were analyzed in mice which received daily IP 100 mg/kg 
olaparib and were culled around 30 days into treatment. 16 
tumours from this cohort were classed as poor responders, 
13 as moderate responders and 18 as good responders.
Assessment of all 16 poorly-responding tumours 
revealed that they were exclusively MSCCs (Figure 6B), 
and were histologically identical to the naïve MSCCs we 
had previously analysed. The moderate responder tumors 
were 38.5% AMEs, 38.5% AC(NST)s and 23% MSCCs 
(Figure 6B). Notably, compared to naïve AC(NST)
s, moderately-responding AC(NST)s showed a higher 
percentage of VIM-positive epithelial cells (18–45%; 
Figure 6C). Moderately-responding MSCCs, in contrast to 
naïve or poor responders, were not composed exclusively 
of fusiform spindle cells; rather, each contained regions 
of cells with epithelial morphology with immunostaining 
patterns similar to naïve AC(NST)s. Moderately-
responding AMEs showed similar staining to naïve AMEs, 
Table 1: Antigen expression patterns in normal mammary epithelium and mesenchymal cells [41, 45–47]
Antigen Normal mammary epithelial distribution
Mesenchymal cell 
marker?
KRT18 Keratin 18 Luminal epithelial cells (cytoplasmic) No
KRT14 Keratin 14 Basal/myoepithelial cells (cytoplasmic) No
TP63 Tumour protein 63 Basal/myoepithelial cells (nuclear) No
ESR1α Estrogen receptor Luminal epithelial cells (cytoplasmic) No
CDH1 E-cadhern Luminal epithelial cells (cell membrane) No
TWIST1 Twist-related protein 1 Basal/myoepithelial cells Yes
Ki67 Proliferation marker protein Ki67 Proliferating cells (nuclear) Proliferating cells (nuclear)
VIM Vimentin Basal/myoepithelial cells Yes
SNAI2 Zinc finger protein Snai2 N/K Yes
ZEB1 Zinc finder E-box binding homeobox 1 N/K Yes
ZEB2 Zinc finder E-box binding homeobox 2 Basal mammary stem cells Yes
Table 2: Summary of immunohistochemical staining patterns for KRT18, KRT14, TP63 and VIM in olaparib-naïve 
and olaparib–resistant tumours
Tumour type Treatment % KRT18+ cells % KRT14+ cells % TP63+ cells % VIM+ cells
AC(NST) (n = 7) Naïve 60–85 0–80 <1 <1
AME (n = 8) Naïve 20–45 1–60 20–60 1–50
MSCC (n = 3) Naïve <1 <1 0 70–85
ASQC (n = 2) Naïve 1–5 50 50–55 <1
AC(NST) (n = 9) Resistant 20–80 1–75 0–10 1–50
AME (n = 3) Resistant 15–40 30–55 10–30 40–50
MSCC (n = 15) Resistant 1–70 0–40 0–5 70–85
ASQC (n = 1) Resistant <1 60 40 30
 AC(NST), adenocarcinoma of no special type; AME, adenomyoepithelioma; MSCC, metaplastic spindle cell carcinoma; 
ASQC, adenosquamous carcinoma.
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with the exception of KRT18 staining which was present 
in less than 1% of tumour cells (compared to 20–45% 
positive cells in naïve tumours; n = 8). The excellent 
responders were predominantly AC(NST)s (89%) with the 
remaining 11% ASQCs (Figure 6B).
Immunohistochemical staining of excellent 
responders showed similarities to naïve tumours, with the 
exception that AC(NST)s showed VIM positivity in up to 
25% of epithelial-like tumour cells. However, excellent 
responders had a significantly lower percentage of VIM 
staining than moderate responders (Figure 6C, p < 0.01). 
We assessed whether percentage of VIM positivity in 
the three responding groups correlated with response to 
olaparib independently of tumour type. In the tumour cells 
of the excellent responders we observed a significantly 
lower percentage of positive VIM staining compared to 
moderate or poor responders. In parallel, the moderate 
responders showed a lower percentage of VIM-positivity 
than the poor responders (Figure 6C), overall indicating 
that the percentage of VIM positivity is inversely 
proportional to the efficacy of the response to olaparib.
To strengthen the correlation, and determine how 
soon/quickly VIM expression was induced after the 
olaparib treatment started, naïve AC(NST) tumours from 
mice treated for 1 hour, 24 hours or 1 week were analysed 
(Figure 6D). Remarkably, we observed a mean incidence 
of ~15% in VIM-stained cells 1 hour post first dose 
(n = 4), but 24 hours after a single dose this had fallen 
back to a mean of 6.75% (range 1–15%; n = 4). After a 
1-week regimen, ~25% of cells in previously treatment-
naïve tumours were VIM positive. Therefore, expression 
of this key marker of EMT was rapid, drug-dependent 
and maintained with extended treatment. Furthermore, 
when we analysed additional markers of EMT olaparib 
(CDH1; TWIST; SNAI2; ZEB1; ZEB2) in AC(NST) 
tumours after a single dose of olaparib, we found a 
significant increase in the proportion of cells staining for 
TWIST, SNAI2, ZEB1 and ZEB2 (p = 0.033, p = 0.043, 
p = 0.033 and p = 0.014 respectively) (Figure 6E).
In summary, these findings indicate that not only 
is innate olaparib resistance associated with EMT in our 
model, but that acquired resistance is also correlated with 
Figure 1: H&E and vimentin staining of tumour phenotypes observed in olaparib-naïve and olaparib-resistant 
tumours in the Brca2/p53-mutant mammary tumour model. Representative pictures of tumour sections stained by H&E, or with 
an antibody against VIM. Scale bars = 50µm. AC(NST) = adenocarcinoma (No Special Type); AME = adenomyoepitheliomas; MSCC = 
metaplastic spindle cell carcinoma; ASQC = adenosquamous carcinoma.
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either mesenchymal-like tumour phenotype or, in those 
tumours that retain a more epithelial-like appearance, the 
rapid treatment-dependent up-regulation of a subset of 
EMT markers.
Upregulation of P-gp is not a mechanism of 
resistance to olaparib in the Brca2-mutant model
Innate resistance to olaparib in a K14Cre Brca2/
Tp53-mutant mouse model showed a link between EMT-
like tumours and high expression of P-gp in a previous 
study [8]. We also previously demonstrated that the 
majority of olaparib-resistant tumours in the BlgCre Brca2/
Tp53-mutant mammary tumour model had increased 
expression of one or more P-gp [3]. To test whether in the 
olaparib-resistant cohort there is a link between the increase 
in proportion of MSCC/EMT-like tumours and the up-
regulation of the P-gp Abcb1a, Abcb1b and Abcg2 [3], we 
compared their expression in olaparib-naïve and olaparib-
resistant tumours. Overall, we did not observe significant 
changes in the expression levels of any relevant P-gp 
between the naïve and resistant tumours (Figure 7A–7C). 
Strikingly, comparison between tumour phenotypes 
showed that MSCCs had significantly higher expression of 
all three receptors compared to AC(NST)s (Figure 7D–7F, 
p = 0.015, p < 0.01 and p = 0.038 respectively). This 
observation was not dependent of treatment, suggesting 
that a high P-gp level is likely to be a characteristic of 
MSCCs in this model. Therefore, the high levels of P-gp 
previously observed in olaparib-resistant tumours [3] are 
likely due to enrichment for MSCCs. 
To shed further light on the functional correlation 
between P-gp upregulation, EMT and PARPi-resistance, 
we treated our mouse models with an alternative PARP 
inhibitor AZD2461, which is not a substrate for P-gp 
[16, 17]. Consistent with the published literature, we first 
Figure 2: Immunohistochemical staining of olaparib-naïve tumours of different phenotypes in the Blg-Cre Brca2/p53-
mutant mammary tumour model. Representative pictures of tumour sections stained with antibodies against either KRT18, KRT14 
or TP63. Scale bars = 50 µm.
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demonstrated that AZD2461 is as effective as olaparib in 
our PARPi-naïve tumours (Figure 8A), and that resistant 
tumours develop on treatment [17], so in these tumours 
at least, P-gp levels are unlikely to be a direct mechanism 
of drug resistance. Interestingly, these AZD2461-resistant 
tumours were also enriched for MSCCs (Figure 8B). In 
a follow up experiment, tumour-bearing mice were first 
treated with daily olaparib; then, when tumours became 
resistant, were switched to AZD2461. As shown in 
Figure 8C, none of these tumours regressed, suggesting 
that if there was a resistance mechanism caused by P-gp 
upregulation, this could not be reversed by a drug that is 
not a P-gp substrate. Furthermore, the spectrum of tumour 
phenotypes was similar to olaparib-resistant tumours 
(Figure 8B). Hence, in this scenario, upregulation of P-gp 
also does not seem to be the direct cause of resistance/
relapse.
We also tested the P-gp inhibitor tariquidar as a 
follow-up therapy on olaparib-resistant tumours in this 
model, using daily IP 2mg/kg Tariquidar 30 minutes 
prior to olaparib dosing. Similarly, we saw no differences 
in the growth curves compared to olaparib, in any of 
the 20 tumours tested (Figure 8D). Again, the resistant 
tumours were enriched for MSCCs (Figure 8B). The 
overall conclusion from these two independent lines of 
experiments is that over-expression of P-gp is associated 
with EMT features in resistant tumours in this model but 
is not the major mechanism of resistance to olaparib.
Resistant tumours accumulate olaparib and have 
reduced PAR levels
Next, to determine whether resistance to PARP 
inhibitors might be explained by pharmacokinetic/
Figure 3: Immunohistochemical staining of olaparib-resistant tumours of different phenotypes in the Brca2/p53-
mutant mammary tumour model. Representative pictures of tumour sections stained with antibodies against either KRT18, KRT14 
or TP63. Scale bars = 50 µm.
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pharmacodynamic (PK/PD) reasons, and whether this 
might correlate with the increase in mesenchymal features 
in resistant tumours, we analyzed olaparib concentration in 
tumours from four cohorts of mice (Figure 9A): olaparib-
naïve mice, taken 1 or 24 hours after a single dose of 
100 mg/kg olaparib, and those in which tumours had 
become resistant to olaparib, taken 1 or 24 hours after a 
final dose of IP 100 mg/kg olaparib.
Olaparib concentrations in naïve tumours one hour 
after a single dose ranged from 0.6–0.93 µM, whilst 
those 24 hours after were significantly lower (<0.1 µM, 
p < 0.01). Olaparib concentrations in resistant tumours one 
hour after their final dose were significantly lower than 
in naïve tumours one hour after a single dose (resistant 
tumours = 0.01–0.628 µM; naïve tumours = 0.6–0.93 µM; 
p < 0.01) but significantly higher than in naïve tumours 
taken 24 hours after a single dose (resistant tumours = 
0.01–0.628 µM; naïve tumours = <0.1 µM; p < 0.01). 
Olaparib concentrations in resistant tumours 24 hours after 
their final dose were similar to those in naïve tumours 
taken 24 hours after a single dose (resistant tumours 
≤0.015–0.16 µM; naïve tumours ≤0.1 µM).
We next analyzed the pharmacodynamics of PAR 
levels in the naïve and resistant tumours, as well as in 
those from mice either 1 or 24 hours after a single dose 
of vehicle and tumours that were responding to a 2-week 
daily dose of IP 100 mg/kg olaparib, and taken 1 hour 
after their final dose (Figure 9B). Both vehicle cohorts 
showed similar PAR levels and did not differ significantly. 
Tumours from naïve mice 1 hour after a single dose of 
olaparib showed reduced PAR levels compared to those 
treated with vehicle, correlating with the high olaparib 
concentration seen in these tumours (p = 0.053). Naïve-
tumours taken 24 hours after a single dose of olaparib 
showed similar PAR levels to those seen in the vehicle-
treated tumours. The 2-week olaparib treatment cohort 
Figure 4: Quantitation of immunohistochemical staining in olaparib-naïve and olaparib-resistant Brca2/p53-mutant 
tumours. VIM (A), KRT18 (B), KRT14 (C) and TP63 (D) positive cells as a percentage of total tumour epithelial cells *p < 0.05, 
**p < 0.01, Mann Whitney U test. Bars represent the mean.
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Figure 5: Olaparib-resistant Brca2/p53-mutant tumours are enriched for an EMT histotype. CDH1/E-Cadherin (A), 
TWIST (B), SLUG (C), ZEB1 (D) and ZEB2 (E) positive cells as a percentage of total tumour epithelial cells. *p < 0.05, **p < 0.01, Mann 
Whitney U test. Bars represent the mean. (F) Proportions of the 4 different tumour types in both olaparib-naïve (n = 20) and olaparib-
resistant (n = 28) tumour cohorts; ***p < 0.001, Chi2 test.
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Figure 6: Olaparib response is correlated with tumour phenotype. (A) Illustrative graph showing examples of relative tumour 
volume (RTV) plots representing poor, moderate and excellent responders. (B) Proportions of the 4 different tumour types in poor (n = 
16), moderate (n = 13) and excellent (n = 18) responder cohorts. (C) VIM expression in different olaparib response groups. Tumours were 
harvested 1 hour after their final dose of olaparib. ***p < 0.001, Mann Whitney U test. (D) VIM expression in AC(NST)s at various stages 
of treatment with olaparib. Tumours were harvested from olaparib-naïve mice (Naïve, n = 8), mice given a single dose (1 hour and 24 
hour, n = 4 per cohort), mice treated daily for one week (1 week, n = 6), mice whose tumours were responding excellently or moderately 
(excellent responder; n = 14, or moderate responder; n = 5) and mice in which tumours had become resistant (resistant, n = 9). All tumours 
were harvested 1 hour after mice were treated with their final dose, except in naïve and 24 hour. **p < 0.01, ***p < 0.001, Mann Whitney 
U test. Black line represents the mean. (E) Additional EMT markers (CDH1; TWIST, SNAI2; ZEB1; ZEB2) in AC(NST)s comparing 
olaparib-naïve tumours and tumours that have seen a single dose of olaparib and taken 1 hour later. *p < 0.05. Note that for ZEB2, five of 
the six naïve tumours analysed showed no staining at all, while one tumour had staining in <1% of cells. In contrast, all four olaparib-dosed 
tumours showed staining, although only in up to 1% of cells. This was sufficient to result in a significant difference between the groups.
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also showed reduced PAR levels compared to vehicle 
(p = 0.021), correlating with these tumours responding to 
PARP inhibitor treatment.
Importantly, PAR levels in resistant tumours taken 
1 hour after their final dose were significantly lower 
compared to the vehicle groups (p = 0.024), independent 
of tumour type. Indeed, levels were similar to those 
seen in naïve tumours 1 hour after a single dose, despite 
olaparib levels in the resistant tumours being lower than 
those in the naïve tumours. PAR levels in resistant tumours 
taken 24 hours after their final dose were not significantly 
different to those treated with vehicle.
Figure 7: Up-regulation of P-gps is correlated with tumour phenotype. (A–C) Expression of Abcb1a (A) Abcb1b (B) and 
Abcg2 (C) in olaparib-naïve tumours (Naïve) compared to olaparib-resistant tumours (Resistant), independent of tumour phenotype. Filled 
or empty markers represent olaparib-naïve or –resistant tumours respectively. (D–F) Abcb1a (D) Abcb1b (E) and Abcg2 (F) expression by 
qRT-PCR in MSCCs compared to AC(NST)s, independent of treatment. *p < 0.05, **p < 0.01, Mann Whitney U test. Error bars represent 
standard deviation.
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These findings suggest that either a sufficient 
concentration of olaparib can be achieved in resistant 
tumours for efficacious inhibition of PARP1, or, that 
the resistant tumours in fact have low levels of PARP1 
expression. As olaparib is thought to have its effect by 
trapping PARP-1 at replicating forks and triggering their 
collapse, this would indicate a potential mechanism 
of resistance. To investigate this, we analyzed PARP1 
levels (Figure 9C). Expression levels were highly 
variable across the cohorts, but there were no significant 
differences between naïve and resistant tumour cohorts, 
and no evidence to suggest that low PAR levels in resistant 
tumours correlated with lower expression of PARP1.
Therefore, PARP1 is expressed in olaparib-resistant 
tumours and sufficient olaparib concentrations can be 
achieved in resistant tumours to suppress its PARylation 
activity. However, it is not clear if the concentration in 
resistant tumours is sufficient for PARP trapping. 
Olaparib-resistant Brca2 tumours remain 
defective for homologous recombination-directed 
DNA repair
PARP-1 inhibition in BRCA-defective tumours is 
expected to cause unrepaired double-stranded breaks in 
DNA [1, 2]. In our model, given that the PK/PD and PARP-1 
Figure 8: Brca2 mammary tumours acquire resistance to AZD2461. (A) Relative Tumour Volume (RTV) plot for AZD2461 
monotherapy administered to BlgCre Brca2/Tp53-mutant mouse mammary model. Each line represents an individual tumour, with an RTV 
of 1 representing tumour size at start of treatment. Black lines are tumours from mice treated daily with vehicle (n = 20), red lines tumours 
from mice treated daily with 100mg/kg AZD2461 (n = 20). (B) Comparison of tumour types between olaparib-naïve tumours (n = 20) and 
those that became olaparib-resistant (n = 20), resistant to AZD2461 monotherapy (AZD2461-resistant, n = 14), resistant to olaparib then 
treated with AZD2461 follow-up therapy (AZD2461 follow-up, n = 20) and resistant to olaparib then treated with the Tariquidar/olaparib 
combination follow-up therapy (Tariquidar follow-up, n = 27). ***p < 0.001, Chi-squared test. (C–D) RTV plots of AZD2461 follow-up (C) 
and Tariquidar (D) therapy. Tumours which developed resistance during daily treatment with 100 mg/kg olaparib (red lines) did not respond 
to follow-up with either daily 100 mg/kg AZD2461 (C, black lines, n = 23) or combination treatment of 2 mg/kg Tariquidar with 100 mg/
kg olaparib (D, black lines, n = 20). Black squares denote the day of switchover from one treatment to the other.
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expression data demonstrate that in olaparib-resistant 
tumours PARP-1 is still expressed and its enzymatic activity 
is being inhibited, these tumours may be able to either 
suppress the DNA damage following PARP-1 inhibition, 
or repair the damage by re-activating homologous 
recombination-directed repair (as reported in other studies, 
although unlikely here considering the nature of the Brca2 
recombined allele used in the study) [10], or alternatively 
tolerate the damage via an as-yet unidentified mechanism.
To address these possibilities, we first analyzed 
levels of DNA damage in olaparib-resistant tumours by 
assessing numbers of γH2AX positive cells. Olaparib-
resistant tumours showed a significant increase in the 
percentage of γH2AX positive cells compared to olaparib-
naïve tumours (Figure 10A, p = 0.006). Comparison of 
Ki67 levels between naïve and resistant tumours showed 
no significant difference for AC(NST)s but a significant 
increase for MSCCs (Figure 10B, p < 0.01), showing that 
although resistant tumours have increased DNA damage, 
the cells are still able to proliferate, particularly in MSCCs.
Having shown that DNA damage is increased in 
olaparib-resistant tumours, we next analysed whether HRR 
Figure 9: Reduced olaparib concentration in olaparib-resistant tumours does not correlate with increased PAR levels. 
(A) Olaparib concentrations in tumours from mice treated with either a single dose of olaparib and taken either 1 hour (olaparib 1 h (N)) or 
24 hours (olaparib 24 h (N)) later, or olaparib-resistant tumours taken either 1 hour (olaparib 1 h (R)) or 24 hours (olaparib 24 h (R)) after 
the final dose. **p < 0.01, Mann Whitney U test. Error bars represent standard deviation. (B, C) Quantitation of western blots performed 
to analyse protein levels of PAR (B) and PARP-1 (C) in tumours from mice treated with a single dose of vehicle and taken either 1 hour 
(vehicle 1 h (N), n = 4) or 24 hours (vehicle 24 h (N), n = 4) later, tumours from mice treated with either a single dose of olaparib and taken 
either 1 hour (olaparib 1 h (N), n = 3) or 24 hours (olaparib 24 h (N), n = 8) later, tumours from mice treated for 2 weeks with daily olaparib 
and taken 1 hour after the final dose (olaparib 1 h (2w), n = 4) or olaparib-resistant tumours taken either 1 hour (olaparib 1 h (R), n = 11) 
or 24 hours (olaparib 24 h (R), n = 8) after the final dose. Vinculin was used as an endogenous control. *p ≤ 0.05, ANOVA.
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could have been restored to repair this damage [7, 9, 18], 
although unlikely in our model, given the permanent 
nature of deletion of the Brca2 conditional allele. We 
analyzed the mRNA expression levels of components 
of the HR pathway using RNAseq. RNA was analyzed 
from tumours that were responding well to olaparib 
(responding; n = 7) or that had responded well initially but 
had become resistant and were at least 5 times larger than 
their smallest size (resistant; n = 22). All mice had received 
daily IP 100 mg/kg olaparib and were culled 1 hour 
after their final dose. Histopathological analysis showed 
that the responding cohort consisted of six AC(NST)
s and one ASQC, whilst the resistant cohort comprised 
13 MSCCs, seven AC(NST)s and two AMEs. Both 
cohorts showed the same IHC staining patterns as other 
excellent responders and resistant tumours, as described 
above. Rad50, Rad51, Rad54b, Mre11a, Palb2, Brca1 
and Bard1 all showed significantly higher expression in 
resistant tumours compared to responding tumours (Figure 
10C–10I, p = 0.05, p < 0.001, p < 0.001, p < 0.001, p = 
0.002, p < 0.001 and p = 0.012 respectively). Importantly, 
however, olaparib-resistant tumours taken 24 hours after 
their final dose were negative for RAD51 foci (Figure 
11), irrespective of tumour phenotype, confirming that 
despite components of the pathway being up-regulated, the 
HRR pathway is compromised in these Brca2 knockout 
tumours, as expected.
DISCUSSION
PARP inhibitors have shown great promise in 
clinical trials and are likely to come into general use in 
HR-deficient (and in particular BRCA1/2 loss of function) 
cancers [19, 20]. However, both primary and acquired 
resistance has been seen in the clinic, and in pre-clinical 
models [3, 4, 7], and a number of mechanisms have been 
proposed. These include up-regulation of P-gps [4], 
restoration of BRCA function by genomic rearrangements 
[7, 10], loss of TP53BP1 [9] and mutations in PARP-1 
[11]. Here we investigated resistance to olaparib in our 
BlgCre Brca2/Tp53-mutant mouse model.
The most striking feature of olaparib-resistant 
tumours was the increase in proportion of MSCCs 
compared to olaparib-naïve tumours, together with 
the partial acquisition of EMT characteristics, such as 
increased VIM and TWIST1, in resistant tumours that 
had not fully acquired the MSCC phenotype. EMT has 
been shown to correlate with drug-resistance in pancreatic 
cancer [21, 22], urothelial cancer [23] and non-small cell 
lung carcinomas [24], and with resistance to a number of 
classes of drugs including cisplatin [25, 26], cyclosporine 
A [27] and adriamycin [28], suggesting that EMT 
conversion is a generic response by tumour cells to toxic 
stresses. Furthermore, previous studies have suggested 
a link between EMT and metabolic reprogramming. 
During EMT cells undergo loss of matrix attachment and 
in mammary epithelial cells overexpressing the ERBB2 
oncogene this has been shown to regulate metabolic 
activity [29]. Metabolic reprogramming as a survival 
strategy in different environments has been demonstrated 
in tumour cells [30–32] and if cells undergoing EMT 
reprogram their metabolic ability this could also contribute 
to acquired resistance.
Innate resistance of MSCC-like tumours to multiple 
drugs, including olaparib, has been previously shown in 
a K14Cre Brca2/Tp53-mutant mouse model [8] and this 
was linked to P-gps. P-gps are transmembrane protein 
pumps belonging to the family of multi-drug resistance 
proteins that are critical in the resistance to a number of 
drugs (reviewed in [33]). The K14Cre Brca2/Tp53-mutant 
mouse model study suggested that the up-regulation of 
these genes contributed to innate resistance, also showing 
that the addition of the P-gp-inhibitor Tariquidar sensitized 
MSCC-like tumours that showed high expression of 
P-gps to the drug therapy [8]. In support of this, we had 
previously published that the majority of olaparib-resistant 
tumours in our model show up-regulation of P-gps [3]. 
However, treatment of animals with olaparib-resistant 
tumours with either a PARP inhibitor with less affinity for 
P-gps, or olaparib in combination with the P-gp inhibitor 
Tariquidar, failed to overcome resistance. Furthermore, 
AZD2461 monotherapy of naïve tumours did not delay 
the appearance of resistance. These findings suggest that 
up-regulation of P-gps is a characteristic of some resistant 
tumours rather than a mechanism of resistance. Supporting 
this, analysis of Abcg2, Abcb1a and Abcb1b showed that 
‘up-regulation’ correlated with tumour phenotype rather 
than olaparib resistance, with all three showing higher 
expression in MSCCs compared to AC(NST)s, suggesting 
that the upregulation of these genes noted previously 
was due to the increase in the proportion of MSCCs in 
olaparib-resistant cohorts.
Analysis of olaparib concentration and PARP 
activity in olaparib-resistant tumours showed that while 
there was a significant reduction in olaparib concentration 
1 hour after their final treatment when compared to 
olaparib-naïve tumours 1 hour after their first treatment, 
PARP activity was still suppressed. This reduction in 
intra-tumoural olaparib levels may in fact be due to up-
regulation of P-gps, but as this does not rescue PARP-1 
PARylation activity it adds further weight to the notion 
that increased drug efflux is not a mechanism of resistance 
to olaparib in our model. The differing results seen 
between our mouse model and the K14Cre Brca2/Tp53-
mutant mouse model may be due to the differences in cell-
of-origin of the tumours, resulting in variances in tumour 
phenotypes, as we have shown in a previous publication 
[15]. Our findings also differ from a Brca1/p53 mutant 
breast cancer model, where sensitivity to olaparib was at 
least partially restored upon either follow-up treatment 
[4, 9]. This suggests that different mechanisms of 
resistance to PARP inhibition must exist in these 
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Figure 10: Olaparib-resistant tumours have DNA damage and show elevated expression of HR-associated genes. 
(A) γH2AX positive cells as a percentage of total tumour cells in olaparib-naïve compared to olaparib-resistant tumours, independent of 
tumour type. **p < 0.01, Mann Whitney U test. Error bars represent standard deviation. (B) Ki67 levels in olaparib-naïve AC(NST)s and 
MSCCs compared to olaparib resistant tumours of the same phenotypes. **p < 0.01, Mann Whitney U test. Error bars represent standard 
deviation. (C–I) Expression levels of Rad50 (C), Rad51 (D), Rad54b (E), Mre11a (F), Palb2 (G), Brca1 (H) and Bard1 (I) comparing 
tumours that were decreasing in size in response to olaparib therapy (Responding) and tumours that became resistant to olaparib therapy 
(Resistant), analysed by RNA-seq. R.P.K.M = reads per kilobase of transcript per million mapped reads. *p < 0.05, **p < 0.01, ***p < 0.001 
Mann Whitney U test. Error bars represent standard deviation.
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genetically distinct mouse models, with important clinical 
implications if such differences were replicated in BRCA1- 
and BRCA2-mutated human breast cancers. 
Restoration of HR by secondary mutations in 
BRCA2 which restore gene function has been shown 
to result in resistance to olaparib [7, 10]. In our BlgCre 
Brca2/Tp53-mutant mouse model, staining for γH2AX 
showed that olaparib-resistant tumours contained high 
levels of DNA damage, but the absence of nuclear Rad51 
focus formation suggests that the HR pathway had not 
been restored. However, we cannot exclude the possibility 
that the response kinetics to olaparib treatment may 
have been altered in the tumours and that restoration of 
HR function may have been delayed. This caveat could 
be resolved by future studies addressing responses at 
additional timepoints after dosing. It also remains formally 
possible that while the reduction in concentration of 
olaparib observed in resistant tumours was not sufficient to 
prevent enzymatic PARylation activity, it was sufficient to 
reduce PARP trapping below a threshold which permitted 
tumour survival. However, a clear biological effect of 
increased γH2AX staining was observed in resistant 
compared to naïve tumours, which would be consistent 
with continuing olaparib-mediated DNA damage events.
Therefore, while we have tested a number of 
hypotheses addressing the underlying resistance mechanism 
in our Brca2 loss-of-function mammary tumour model, 
including upregulation of P-gp, altered PD/PK, loss of 
expression of the drug target and restoration of HRR, none 
of these hypotheses can be supported. Indeed, the only 
strong correlate of either primary resistance or relapse on 
therapy remains EMT and the rapid expression of EMT-
Figure 11: Olaparib-resistant tumours do not have Rad51 foci. Rad51 staining in intestinal cells of a BRCA2 wild-type mouse 
taken 24 hours after a single dose of 10 mg/kg cisplatin (BRCA2 proficient cisplatin) and either a mammary tumour from a mouse treated 
with a single dose of olaparib and taken 24 hours later (BRCA2 deficient olaparib) or a olaparib-resistant tumour taken 24 hours after the 
final dose (Resistant olaparib) from our Brca2/p53-mutant mammary tumour model. Scale bars represent 10 µm. Pictures taken with Zeiss 
LSM710 confocal microscope using a 60× objective.
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associated markers in a treatment-dependent manner. 
A recent study in small cell lung cancer identified a link 
between EMT and resistance to PARP inhibitors in that 
disease setting [34] and PARP-1 has been shown to regulate 
EMT in prostate cancer models through regulation of TGFβ 
signalling and changes in levels of ZEB1 [35]. Therefore, 
it is likely that some as-yet undefined aspect of the biology 
of mesenchymal cells is responsible for the PARP-
inhibitor resistance phenotype across a variety of tissues. 
Importantly, we now show the rapidity of this response, 
making interventions which could block this process or 
target the underlying mechanism attractive options for 
olaparib combination therapy.
MATERIALS AND METHODS
Animal model and genotyping
All animal procedures were carried out according 
to current UK Home Office regulations following local 
ethical committee approval and under the authority of 
the appropriate personal and project licenses. ARRIVE 
guidelines were followed.
The Brca2-mutant model has previously been 
described [3]; in brief, these mice carry a Cre transgene 
under the control of the Blg promoter, and floxed alleles for 
Brca2 and p53. Mice were maintained on an outbred, Black 
6 (C3H) background and were fed standard diet and water 
ad libitum. Female mice developed mammary tumours 
from six months of age, with a median of nine months. 
PCR conditions for the Blg-Cre transgene and the Brca2fl 
and p53fl alleles have been previously described [36–38].
Drug formulations and dosing
Olaparib was prepared as described previously 
[3] and injected at 100 mg/kg by single bolus injection. 
AZD2461 was made up at 10 mg/ml in methylcellulose, in 
a foil-wrapped glass vial with continuous stirring at room 
temperature, and administered by oral gavage at 100 mg/kg. 
Tariquidar was diluted to 0.2 mg/ml in 5% dextrose and 
IP-injected at 2 mg/kg 30 minutes before olaparib. 
Tumour analysis 
Tumour size was analysed as described previously 
[3]. Detailed histopathological analysis was performed 
blinded to tumour response using previously-established 
criteria [14, 15] based on human breast tumour 
classification [39].
Immunohistochemistry
Immunohistochemistry for KRT18, KRT14, 
TP63, ESR1α, CDH1, TWIST1 and Ki67 used mouse 
monoclonal antibodies (see Table 3 for antibody details). 
VIM was detected using a goat polyclonal antibody and 
SNAI2, ZEB1 and ZEB2 were detected using rabbit 
monoclonal antibodies. All stains, other than Ki67, were 
scored as previously described [14, 15]. Ki67 was scored 
blind by manually counting the number of positive cells 
per image using Image J software. 
Immunofluorescence
RAD51 and γH2AX staining used mouse 
monoclonal antibodies, modifying the protocol described 
in [40]. Antigen retrieval was performed by microwaving 
under pressure in Citrate buffer (DAKO). Slides were then 
incubated with 0.2% Triton for 20 minutes, washed in PBS 
and treated with DNAse I for 1 hour at 37° C. This was 
followed by incubation with immunofluorescence buffer 
(IFF;1% bovine serum albumin, 2% FBS in PBS) for 
1 hour at room temperature (RT). The primary antibody 
diluted in IFF was applied overnight at 4° C, washed 
with PBS followed by anti-mouse secondary antibody 
(M.O.M kit, Vector labs, 1:250 dilution) for 30 minutes 
at RT. Signal was amplified using ABC reagents (Vector 
labs) for 30 minutes at RT. Sections were then incubated 
with TSA reagents (PerkinElmer) for 10 minutes at room 
temperature and washed in DAPI (1:10,000 dilution) 
for 15 minutes. Sections were fixed with 4% PFA and 
mounted. Images were analysed by manually counting 
cells using Image J software.
RNA expression analysis
For qRT-PCR analysis of gene expression, frozen 
tumour material was prepared using the Maxwell 
SimplyRNA LEV Tissue Kit for automated extraction of 
total RNA (Promega, UK). Briefly, a micro-pestle was 
used to grind frozen tumour material, on dry ice, prior to 
adding homogenisation buffer containing 1-Thioglycerol 
and an equal volume of lysis solution, and the relevant 
program used for automated RNA extraction with DNase1 
treatment. Samples were stored at −80° C until used for 
cDNA synthesis, where 1 µg of RNA per sample was 
converted to cDNA using the Quantitect cDNA Synthesis 
Kit (Qiagen, UK). qPCR reactions were performed using 
the cDNA as described previously [41]. Details of Taqman 
probes can be found in Table 3. All results were calculated 
using the ∆−∆Ct method. Data were expressed as the mean 
fold gene expression difference over comparator samples 
with 95% confidence intervals. 
For gene expression analysis by RNA-seq, tumours 
from all response groups were lysed in chilled Qiazol in a 
Qiagen Tissue lyser using stainless steel beads. The lysate 
was incubated at RT for 5 minutes. One-fifth volume of 
chloroform was added and the sample was then vortexed 
for 15 seconds followed by a further 3 minutes incubation 
at RT. Phase separation was performed by 15 minutes 
centrifugation at 13,000 RPM at 4° C. The upper aqueous 
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phase was loaded into a Qiacube and RNA was extracted 
using the Qiagen miRNeasy kit with on-column DNase1 
treatment. The quality of RNA was analysed on the 
Agilent 2100 bioanalyser using Agilent RNA 6000 Nano 
chip and small RNA chips. 5 µg was submitted for library 
preparation and sequencing.
Library preparation for RNA-seq
Samples were riboRNA depleted using Ribo-
Zero™ rRNA Removal Kit (Epicentre) according to the 
manufacturer’s instructions. The final depleted RNA was 
checked by Qubit assay and Bioanalyzer RNA pico chips 
Table 3: Details of antibodies used in immunohistochemistry and western blotting and Taqman probes used for qRT-
PCR analysis
Antibody clone, dilution and source details
Antigen Clone Dilution Source
KRT18 65028 1:5 Progen Biotechnik GmbH, Heidelberg, Germany
KRT14 ab7800 1:500 Abcam, Cambridge, UK
TP63 ab735 1:100 Abcam, Cambridge, UK
ESR1α VP-E613 1:500 Vector Laboratories, Peterborough, UK
CDH1 610182 1:300 BD transduction laboratories, California, USA
TWIST1 ab50887 1:500 Abcam, Cambridge, UK
Ki67 VP-K452 1:20 Vector Laboratories, Peterborough, UK
VIM SC-7557 1:300 Santa Cruz Biotechnology, Texas, USA
SNAI2 C19G7 1:100 Cell Signalling Technology, Massachusetts, USA
ZEB1 NBP1-05987 1:500 Novus Biologicals, Colorado, USA
ZEB2 NBP1-82991 1:500 Novus Biologicals, Colorado, USA
RAD51 GTX70230 1:100 Genetex Inc., Texas, USA
γH2AX 05-636 1:200 Merck Millipore, Maddachusetts, USA
PAR 4336-BPC-100 1:1000 Trevigen, Maryland, USA
PARP-1 9452 1:1000 Cell Signalling Technology, Massachusetts, USA
VCL ab18058 1:5000 Abcam, Cambridge, UK
Mouse HRP-
conjugated 7074 1:2000 Cell Signalling Technology, Massachusetts, USA
Rabbit HRP-
conjugated 7076 1:2000 Cell Signalling Technology, Massachusetts, USA
Mouse Biotinylated PK-2200 1:200 Vector Laboratories, Peterborough, UK
Rabbit Biotinylated E0432 1:200 DAKO/Agilent, Santa Clara, USA
Goat Biotinylated E0466 1:200 DAKO/Agilent, Santa Clara, USA







HRP-conjugated antibodies were used as secondary antibodies in western analysis; biotinylated antibodies were used as 
secondary antibodies in immunohistochemical analysis. Probes were purchased from Thermo Fisher Scientific. Actb and 
Gapdh were used as endogenous controls.
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and 50 ng used in the ScriptSeq v2 protocol (Epicentre). 
Libraries were quantified by Qubit assay and checked for 
size range on a Bioanalyser DNA high sensitivity chip. 
The libraries were quantified by qPCR, using an Illumina 
Library Quantification Kit (KAPA, KK4854,) on a Roche 
LightCycler 480II system.
Small RNA libraries were prepared from total RNA 
using NEBNext® Multiplex Small RNA Library Prep Set 
for Illumina® according to the manufacturer’s instructions. 
Samples were pooled on an equimolar basis and the small 
RNA fraction selected using Sage Pippin Prep (selecting 
between 130-170 bp).
RNA-seq 
RNA-seq libraries were sequenced using 100 
bp paired-end reads on the Illumina Hi-Seq platform 
at 150-fold coverage (100 million reads, 3 samples per 
lane). Sequencing of small RNAs was performed on 
eight lanes of the Hi-Seq platform using 1× 75bp single 
reads. Sequencing reads which were of low quality or 
contained polyA and adapters were pre-filtered before 
mapping. Filtered reads were mapped to the mm10 mouse 
genome using Tophat [42] and gene-level counts generated 
using HTSeq [43]. Differentially-expressed genes were 
identified using the DESeq R package [44]. 
Pharmacokinetics/pharmacodynamics of 
olaparib in Brca2/p53 mutant mammary 
tumours
Samples were analysed for olaparib using a protein 
precipitation extraction procedure, followed by LC-MS/
MS detection. A stock (2 mM) of the analytical standard 
was prepared using DMSO and subsequently used to 
produce spiking solutions. 47.5 µl of the required blank 
matrix was aliquoted into a 96 well plate and the matrix 
was subsequently spiked with 2.5 µl of each dilution to 
give a final concentration range of 1 nM–10,000 nM. 
50 µl of each sample and standards were quenched with 
acetonitrile with internal standard, mixed, and spun 
in a centrifuge at 3000 rpm for 15 minutes. 50µl of the 
supernatant was then diluted 10-fold with deionised water 
and the samples analysed by LC-MS/MS using Masslynx 
and processed using Quanlynx.
For analysis of poly(ADP-ribose) (PAR) and PARP-1 
levels flash-frozen pieces of tumor were lysed in ice-cold 
buffer containing Tris–NaCl pH7.5 20 mmol/L, NaCl 
137 mmol/L, NP40 1%, glycerol 10%, supplemented 
with NaF 50 mmol/L, Na3VO4 1 mmol/L, Protease 
complete Inhibitor tablet (Roche 1836145), Phosphatase 
inhibitor cocktails 2 and 3 (Sigma, P0044 and P5726). 
Homogenization was performed 3 times using Fastprep 
tubes (MP Biomedicals #6910-500) and MP Biomedicals 
Fast Prep-24 machine. All samples were sonicated for 30 
seconds using high amplitude (Diagenode), centrifuged 
at 13,000rpm 4º C for 10 minutes and the supernatants 
were collected. Protein concentration was calculated using 
Pierce Protein Assay Reagent A plus BCA Protein Assay 
Reagent B. A total of 40 µg of protein were separated on 
4–12% SDS-PAGE gels (Invitrogen) at 180V (for 1 hour) 
in 1× NUPAGE MES SDS running buffer (Invitrogen) 
in the presence of NuPAGE antioxidant (Invitrogen). 
Proteins were electrotransferred to 0.2 um nitrocellulose 
membranes (Invitrogen) using an Iblot dry blotting system 
(Invitrogen) (20V for 7 min). Membranes were blocked 
for 1 hour in 5% milk in Tris-buffered saline (TBS)-
Tween and then hybridized using the primary antibodies 
overnight at 4o C in 5% BSA TBS-Tween: rabbit anti-
PAR, rabbit anti-PARP1, mouse anti-VCL. Mouse 
and rabbit horseradish peroxidase (HRP)-conjugated 
secondary antibodies were diluted in 5% milk in TBS-
Tween, incubated with blots for 1 hour and proteins were 
detected with SuperSignal West Dura Chemiluminescent 
Substrate reagent (Pierce Thermo Scientific). See Table 3 
for antibody details. Biomarker signals were quantified 
using Genetools software and normalized to VCL control. 
Statistics
Statistical analysis was performed using the non-
parametric two-tailed Mann–Whitney U test, except for 
comparison of tumour proportions, which was conducted 
by Chi Squared test and analysis of PAR and PARP-1 
levels, which were calculated using VCL-normalised 
logged (log10) data by ANOVA. P ≤ 0.05 was considered 
to be statistically significant. All error bars on graphs 
represent standard deviations.
Abbreviations
AC(NST): Adenocarcinoma/invasive ductal 
carcinoma of no special type; AME: Adenomyoepithelioma; 
ASQC: Adenosquamous carcinoma; EMT: Epithelial-
mesenchymal transition; HR: Homologous recombination; 
HRR: Homologous recombination repair; MSCC: 
Carcinosarcoma/metaplastic spindle cell carcinoma; 
PAR: Poly (ADP-ribose); PARP: Poly (ADP-
ribose) polymerase; P-gp: Phosphoglycoprotein; PK: 
Pharmacokinetic; PD: Pharmacodynamic.
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